Recombinant human erythropoietin in nephrology

W. Samtleben*, P. Ivanovich, H. J. Gurland

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

3 Scopus citations


rEPO therapy provides a unique opportunity to correct anemia in end-stage renal failure patients. Complete correction of the anemia, although possible, has some obvious disadvantages over a partial correction with a target hemoglobin of 10-13 g/dl or a hematocrit of 30-35%, respectively. Unresponsiveness to rEPO seems to be rare; in most cases the predicted hemoglobin increase could be seen as soon as an underlying iron deficiency was treated adequately. Blood loss and aluminum toxicity are the next most frequent reasons for an inadequate response to rEPO. Hypertension (and its complications) as well as fistula clotting are the most important side-effects which require close attention when patients at risk for these complications are treated with rEPO.

Original languageEnglish (US)
Pages (from-to)607-612
Number of pages6
JournalBiomedicine and Pharmacotherapy
Issue number8
StatePublished - 1989
Externally publishedYes


  • anemia
  • erythropueitin
  • renal failure

ASJC Scopus subject areas

  • Pharmacology


Dive into the research topics of 'Recombinant human erythropoietin in nephrology'. Together they form a unique fingerprint.

Cite this